▌Top Stocks · LIFE SCIENCES TOOLS·Updated August 14, 2026
Life Sciences Tools Stocks to Own in August 2026: 7 Quality Names
A seven-stock countdown explores quality across life sciences tools, from challenged platforms to profitable analytical, diagnostic, and research franchises.
Top Stocks · LIFE SCIENCES TOOLSUpdated August 14, 2026
Life sciences tools companies are the picks-and-shovels businesses behind drug discovery, translational research, and molecular diagnostics. Their instruments, reagents, consumables, software, and services are embedded in laboratory workflows, giving successful platforms the potential to monetize an installed base repeatedly. That matters in August 2026, when investors are looking for healthcare exposure with more recurring demand than a single-product biotechnology story. The strongest companies in this group combine mission-critical products with broad customer exposure across pharmaceutical, biotechnology, academic, clinical, and government laboratories.
The opportunity spans several layers: sample preparation and reagents, analytical instruments, sequencing and genomics, spatial biology, proteomics, workflow software, and downstream service contracts. Long-term growth in biologics, cell and gene therapy, spatial biology, proteomics, and next-generation sequencing supports specialized workflows and consumable demand. Industry developments reinforce that model: Illumina reported in 2025 that sequencing consumables grew and that NovaSeq X was driving higher recurring demand, while Thermo Fisher highlighted a 2025 filtration and separation acquisition to deepen its bioproduction exposure.
This countdown ranks seven US-listed life sciences tools stocks by investment quality, not simply by size or thematic excitement. The analysis weighs profitability, growth, valuation, earnings execution, analyst sentiment, and our composite quality grades. The ranking begins with the most challenged name at #7 and works down to the best-ranked stock at #1, so readers can distinguish speculative platform potential from established financial strength.
Our filter covered US-listed companies with market capitalizations above $500 million and placed investment quality at the center of the ranking. We considered operating and net profitability, revenue and earnings growth, trailing and forward valuation where available, recent earnings surprises, analyst consensus, and the composite quality grade. The list is a countdown: #7 appears first, while the best pick is reserved for #1. The figures reflect the supplied August 2026 data snapshot and are intended to support comparison rather than replace individual due diligence.
Market cap: $0.3B · Quality grade: C · Analyst consensus: Hold (avg target $1.35)
What they do. The company develops and sells instrumentation, consumables, assays, and services for scientists and biomedical researchers through its Proteomics and Genomics segments. Its portfolio includes the SomaScan protein-measurement platform, CyTOF multiplexed analysis, Hyperion spatial biology, and the Biomark X9 system for high-throughput quantitative PCR, creating a model that combines equipment placements with consumable and assay usage.
Why it fits. Standard BioTools has direct exposure to several of the theme's most important workflows: proteomics, genomics, multiplexed cell analysis, spatial biology, and molecular diagnostics. SomaScan and CyTOF can deepen research insight across proteins and cells, while Hyperion preserves spatial context in tissue analysis. Those specialized platforms fit the industry's recurring consumables-and-assays model, but the company's smaller scale makes execution especially important.
Numbers that matter. Revenue was $84.6 million and declined 7.6% year over year, while trailing EPS was negative $0.13 and next-year EPS is estimated at negative $0.16. Gross margin was 56.5%, but operating margin was negative 38.94% and EBITDA was negative $50.99 million. The supplied market-cap and revenue figures imply roughly 3.5 times sales; the quote data also shows a negative P/E of -10.71, underscoring why profitability weighs heavily on this ranking. The reported net-margin field is 100.37%, which is inconsistent with the operating-loss and EBITDA figures, so operating performance is the clearer quality signal.
Recent momentum. In the August 5, 2026 quarter, EPS was negative $0.05 versus a negative $0.03 estimate, a 66.7% miss. Standard BioTools has beaten estimates in only 2 of the last 8 reported quarters. The analyst breakdown lists one Hold, with an average target of $1.35, providing limited evidence of broad conviction despite the platform's thematic relevance.
What they do. Revvity provides health sciences instruments, reagents, software, subscriptions, detection and imaging technologies, and related services. Its diagnostics portfolio supports early detection and testing for genetic, metabolic, infectious, and other conditions, while its research products support genomics, oncology, immunodiagnostics, and drug discovery. The combination of instruments, assay platforms, software, warranties, training, and subscriptions gives the company several ways to generate revenue around laboratory workflows.
Why it fits. Revvity touches both research and clinical applications, giving investors exposure to the diagnostic and life sciences tools layers of the market. Its genomic workflow technologies, detection systems, reagents, and software are relevant to drug discovery and disease screening, while recurring assay and subscription activity can complement capital equipment sales. That breadth makes it a more diversified theme exposure than a single-platform specialist.
Numbers that matter. Revenue was $2.91 billion, up 1.3% year over year, and earnings growth was 1.1%. Gross margin was 55.0%, operating margin was 17.03%, and net margin was 8.16%, with EBITDA of $866.9 million. Trailing P/E was 55.6x versus a forward P/E of 21.8x; the supplied market-cap and revenue figures imply approximately 4.5 times sales. Trailing EPS was $2.12, while next-year EPS is estimated at $5.8919, suggesting that the valuation depends substantially on earnings improvement.
Recent momentum. Revvity's August 4 quarter produced EPS of $1.41 against a $1.23 estimate, a 14.6% beat, and the company has beaten estimates in all 8 of the supplied quarters. Analysts list 2 Buys and 7 Holds, with no Sell rating shown in the breakdown. The $121.07 average target and Buy consensus indicate constructive sentiment, although the relatively modest revenue growth and debt-equity component rated Sell remain considerations.
What they do. Bio-Techne develops and sells life sciences reagents, instruments, and services through Protein Sciences and Diagnostics and Spatial Biology. Its products include cytokines, growth factors, antibodies, small molecules, tissue-culture sera, cell-selection technologies, automated western blot and multiplexed ELISA tools, diagnostic assays, spatial genomics products, and molecular controls. This mix gives the company recurring reagent demand alongside specialized instruments and workflow products.
Why it fits. Bio-Techne is closely aligned with the biological research layer of life sciences tools. Protein reagents and cell-selection products support drug discovery and cell and gene therapy, while spatial biology, tissue analysis, and diagnostic products address newer, higher-information workflows. Its exposure to antibodies, growth factors, protein analysis, and spatial genomics gives investors a way to participate in several secular research trends without relying on one instrument category.
Numbers that matter. Revenue was $1.21 billion, down 1.5% year over year, but earnings growth was 128.6%. Gross margin reached 66.4%, operating margin was 25.19%, net margin was 9.05%, and EBITDA was $366.0 million. Trailing P/E was 103.2x and forward P/E was 34.5x; market cap divided by revenue implies roughly 9.3 times sales, the richest sales multiple among the seven names using the supplied figures. EPS was $0.70 on a trailing basis, with next-year EPS estimated at $2.0435.
Recent momentum. Bio-Techne reported August 12 EPS of $0.49 versus a $0.46 estimate, a 6.5% beat, and its eight-quarter record stands at 6 beats. The analyst breakdown includes 3 Buys and 5 Holds, with an average target of $69.73. The earnings recovery is encouraging, but the negative revenue growth and elevated valuation leave less room for execution disappointments.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Waters designs, manufactures, sells, and services liquid chromatography and mass spectrometry systems, columns, and other consumables. Its TA segment supplies thermal analysis, rheometry, and calorimetry instruments, while software interfaces with its own and other manufacturers' instruments. Customers include pharmaceutical, clinical, academic, industrial, environmental, and government laboratories, and the business model combines instrument placements with recurring columns, consumables, software, and service.
Why it fits. Waters sits in the core analytical-instrument layer of the theme, where laboratories use chromatography and mass spectrometry for drug development, clinical testing, protein analysis, environmental work, and quality control. Its columns and other consumables can monetize each installed system over time, while software and servicing deepen workflow integration. That recurring component is important, but the company's exposure to laboratory capital budgets makes cycle management equally relevant.
Numbers that matter. Revenue was $4.64 billion, with reported year-over-year revenue growth of 113.3%, while earnings growth was negative 3.1%. Gross margin was 56.3%, operating margin was 10.03%, net margin was 3.59%, and EBITDA was $1.45 billion. Trailing P/E was 105.4x versus a forward P/E of 28.4x; the supplied market-cap and revenue figures imply roughly 6.7 times sales. The low current net margin and strong forward-versus-trailing valuation gap make execution and earnings normalization central to the thesis.
Recent momentum. Waters beat its August 4 EPS estimate with $3.05 versus $3.01, a 1.3% surprise, and has beaten in all 8 supplied quarters. The May quarter was stronger, with EPS of $2.70 against $2.31, a 16.9% beat. Analysts list 1 Buy and 15 Holds, producing a Hold consensus and a $436 average target. That record supports operating consistency, but the heavily Hold-weighted view suggests limited consensus for aggressive upside.
What they do. Agilent provides application-focused solutions across life sciences, diagnostics, and applied chemical markets. Its portfolio includes liquid chromatography and mass spectrometry, genomics and pathology products, gas chromatography, spectroscopy, vacuum technology, and laboratory informatics. The Agilent CrossLab segment adds repairs, maintenance, installations, training, compliance support, software as a service, asset management, consulting, consumables, and laboratory software, creating a broad service and recurring-revenue layer around instruments.
Why it fits. Agilent is a strong example of the theme's shift from one-time equipment sales toward a fuller workflow relationship. CrossLab's columns, sample-preparation products, maintenance, software, and compliance services can monetize instruments after installation, while the Life Sciences and Applied Markets segments provide exposure to pharmaceutical research, diagnostics, environmental testing, and chemical analysis. Its breadth also reduces dependence on one research application.
Numbers that matter. Revenue was $7.232 billion, up 10.0% year over year, while earnings growth was 60.0%. Profitability was stronger than most names below it: gross margin was 52.6%, operating margin 23.71%, and net margin 19.55%, with EBITDA of $2.015 billion. Return on equity was 21.33% and return on assets was 8.61%. Trailing P/E was 30.0x and forward P/E 22.1x; the supplied market-cap and revenue figures imply approximately 5.8 times sales.
Recent momentum. Agilent's May 27 quarter delivered EPS of $1.49 versus a $1.41 estimate, a 5.7% beat. The supplied history shows 5 beats in 7 reported quarters, with one quarter matching estimates and one modest miss. Analysts list 4 Buys and 3 Holds, with a Buy consensus and a $159.32 average target. The next reported estimate is $1.48 for August 26, so near-term execution remains a visible catalyst and test.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The screen began with US-listed companies classified within life sciences tools and services or closely related diagnostics and research categories, subject to a market-cap threshold above $500 million. Stocks were ranked by investment quality using a composite of profitability, revenue and earnings growth, valuation, balance-sheet considerations, earnings-surprise history, analyst consensus, and the supplied quality grade. No single metric determined the order: strong growth could not fully offset persistent losses, while reliable earnings execution could not erase an excessive valuation. The ranking is refreshed monthly so changes in financial results, estimates, market capitalization, and sentiment can alter the countdown over time.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
